Evidence map›Paper›PMID 26661258›Full record

ArticleInternational urology and nephrology2016

Predictive modeling using a nationally representative database to identify patients at risk of developing microalbuminuria.

Lorenzo Villa-Zapata, Terri Warholak, Marion Slack, Daniel Malone, Anita Murcko, George Runger, Michael Levengood

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Lorenzo Villa-ZapataFacultad de Farmacia, Universidad de Concepción, Barrio Universitario s/n, Concepción, Chile. lorenzovilla@udec.cl.ORCID http://orcid.org/0000-0002-3821-4595
Terri WarholakCenter for Health Outcomes and PharmacoEconomic Research, University of Arizona, College of Pharmacy, 1295 N. Martin, Tucson, AZ, 85721, USA. warholak@pharmacy.arizonaedu.
Marion SlackPharmacy Practice and Science, University of Arizona, College of Pharmacy, 1295 N. Martin, Tucson, AZ, 85721, USA. slack@pharmacy.arizona.edu.
Daniel MalonePharmacy Practice and Science, University of Arizona, College of Pharmacy, 1295 N. Martin, Tucson, AZ, 85721, USA. malone@pharmacy.arizona.edu.
Anita MurckoBiomedical Informatics, Arizona State University, 550 N. 3rd Street, Phoenix, AZ, 85004-0698, USA. Anita.Murcko@asu.edu.
George RungerBiomedical Informatics, Arizona State University, Mayo Clinic, Samuel C. Johnson Research Bldg. 13212 East Shea Boulevard, Phoenix, AZ, USA. George.Runger@asu.edu.
Michael LevengoodCollege of Pharmacy, The University of Arizona, 1295 N. Martin, Tucson, AZ, 85721, USA. mjlevengood@gmail.com.
University of Arizona · USArizona State University · USMayo Clinic in Arizona · USUniversity of Concepción · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePredictive models allow clinicians to identify higher- and lower-risk patients and make targeted treatment decisions. Microalbuminuria (MA) is a condition whose presence is understood to be an early marker for cardiovascular disease. The aims of this study were to develop a patient data-driven predictive model and a risk-score assessment to improve the identification of MA.

methodsThe 2007-2008 National Health and Nutrition Examination Survey (NHANES) was utilized to create a predictive model. The dataset was split into thirds; one-third was used to develop the model, while the other two-thirds were utilized for internal validation. The 2012-2013 NHANES was used as an external validation database. Multivariate logistic regression was performed to create the model. Performance was evaluated using three criteria: (1) receiver operating characteristic curves; (2) pseudo-R (2) values; and (3) goodness of fit (Hosmer-Lemeshow). The model was then used to develop a risk-score chart.

resultsA model was developed using variables for which there was a significant relationship. Variables included were systolic blood pressure, fasting glucose, C-reactive protein, blood urea nitrogen, and alcohol consumption. The model performed well, and no significant differences were observed when utilized in the validation datasets. A risk score was developed, and the probability of developing MA for each score was calculated.

conclusionThe predictive model provides new evidence about variables related with MA and may be used by clinicians to identify at-risk patients and to tailor treatment. The risk score developed may allow clinicians to measure a patient's MA risk.

Indexed as

Models, StatisticalAdultAlbuminuriaBiomarkersDatabases, FactualFemaleHumansMaleMiddle AgedNutrition SurveysPredictive Value of TestsProspective StudiesRisk AssessmentRisk FactorsROC CurveUnited StatesBiomarkersAlbuminuriaMicroalbuminuriaPredictive modelProteinuria

Identifiers

PMID26661258
OpenAlexW2216647138

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.